Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
CA 2443258 A1 · Owner: Vignuzzi, Marco · Inventors: Escriou, Nicolas; Gerbaud, Sylvie; Van Der Werf, Sylvie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to replicons or self-replicating RNA molecules derived from the genome of cardioviruses and aphtoviruses which can be used , to express heterologous proteins in animal cells. When injected in an animal host, for example in the form of naked RNA these replicons permit the , translation of the encoded heterologous protein. If the encoded heterologous protein is a foreign antigen, these replicons induce an immune response against the encoded heterologous protein. The invention uses cardiovirus and aphtovirus genomes to construct these replicons. The invention demonstrates that these replicons, when injected as naked RNA can induce immune responses , against a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.